Skip to main content


A study by Cordant Health Solutions and Northwest Integrated Health found that OUD patients who had been prescribed buprenorphine demonstrated higher retention rates and improved health outcomes when receiving medication at office visits instead of retail pharmacies.
A decision made by HHS in the waning days of the Trump presidency to publish new guidelines that include an exemption from certain requirements under the Controlled Substances Act for physicians who are licensed under state law and possess DEA registration to prescribe buprenorphine appears to be poised for reversal under the Biden administration.
With more than 40 states reporting an increase in overdose deaths during the COVID-19 pandemic, the American Medical Association, in partnership with the firm Manatt Health, has published an update to its National Roadmap on State-Level Efforts to End the Nation’s Drug Overdose Epidemic.
Spark Biomedical, a Texas-based medical device company, announced that the FDA has granted 510(k) clearance for its Sparrow Therapy System, a wearable neurostimulation device for the treatment of opioid withdrawal.
While providers wait for vaccines to slow the COVID-19 pandemic and better treatments to reduce the death toll among those infected, there are steps that can be taken to help address the “other” surge—in the opioid crisis.
Back to Top